Generate:Biomedicines is the latest biotech to benefit from a renewed appetite from investors for publicly listed drug developers. Generate—which will list its stock on the Nasdaq this morning under ...

Feb 26 (Reuters) - Generate Biomedicines said on Thursday that it raised $400 million in its U.S. initial public offering, pricing shares of the U.S.-based drug developer at $16 each. The offering ...

Generate:Biomedicines is hoping to raise up to $425 million via a Nasdaq IPO, with the proceeds needed to bankroll its lead antibody through respiratory disease trials. The Flagship Pioneering-founded ...

Generate Biomedicines Inc., a biotechnology firm using artificial intelligence in drug development, is seeking to raise as much as $425 millon in an initial public offering, as listing activity in the ...

The Northwest’s only commercial nuclear power plant, the Columbia Generating Station, was manually shut down early Thursday morning due to a mechanical problem. Energy Northwest workers shut the plant ...

Seedance 2.0 can take camera movement, visual effects, and motion into account. Seedance 2.0 can take camera movement, visual effects, and motion into account. is a news writer who covers the ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Generate:Biomedicines raised ...

The tax-filing season is officially underway, and investors – especially those who are holding income-generating assets – will want to prepare to pay the tax man. The Internal Revenue Service began ...

Apple Music is now available as an extension within ChatGPT, meaning you can search for songs, create playlists, and discover new music through OpenAI's chatbot. Here's how to set it up and what makes ...

Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with content, and download exclusive resources. Agent workflows make transport a first-order ...

Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing a blockbuster sales potential for ...

Recursion Pharmaceuticals Inc (NASDAQ: RXRX) shares moved higher Wednesday after JPMorgan upgraded the stock to Overweight from Neutral and lifted its price target to $11 from $10. What Happened: ...